| pubmed-article:20878981 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0042037 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0334227 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:20878981 | lifeskim:mentions | umls-concept:C0765701 | lld:lifeskim |
| pubmed-article:20878981 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20878981 | pubmed:dateCreated | 2011-7-22 | lld:pubmed |
| pubmed-article:20878981 | pubmed:abstractText | Cytokines may play a role in the initiation and progression of prostate cancer. A cytokine antibody array was previously applied to prostatic fluid obtained from patients with prostate cancer, and interleukin 18 binding protein (IL-18BP), a potent inhibitor of interleukin 18, was noted to be significantly upregulated in cases with large volume disease. We sought to further characterize the association of IL-18BP with prostate cancer and determine whether IL-18BP levels in patient serum and urine samples had clinical relevance. IL-18BP was expressed and secreted by the prostate cancer cell lines DU145 and PC3 but not by LNCaP and CWR22, upon interferon-? (IFN-?) stimulation. IFN-?-induced secretion of IL-18BP was enhanced by added TNF-?, IFN-? and IFN-?. The IL-18BP secreted from DU145 and PC3 functionally inhibited IL-18. Immunohistochemical analyses showed positive IL-18BP staining in prostate cancer cells as well as in macrophages in radical prostatectomy specimens. Significant differences in urinary IL-18BP levels (normalized by total protein) collected post-DRE were found between cases with and without cancer on biopsy (p = 0.02) and serum IL-18BP levels correlated with Gleason score (p = 0.03). Our finding of elevated IL-18BP secretion from prostate cancer cells suggests an attempt by cancer to escape immune surveillance. IL-18BP merits further study as a marker of aggressive prostate cancer and as a therapeutic target. | lld:pubmed |
| pubmed-article:20878981 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20878981 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20878981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20878981 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20878981 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:20878981 | pubmed:issn | 1097-0215 | lld:pubmed |
| pubmed-article:20878981 | pubmed:author | pubmed-author:PavlovichChri... | lld:pubmed |
| pubmed-article:20878981 | pubmed:author | pubmed-author:IsaacsWilliam... | lld:pubmed |
| pubmed-article:20878981 | pubmed:author | pubmed-author:EwingCharles... | lld:pubmed |
| pubmed-article:20878981 | pubmed:author | pubmed-author:FujitaKazutos... | lld:pubmed |
| pubmed-article:20878981 | pubmed:copyrightInfo | Copyright © 2010 UICC. | lld:pubmed |
| pubmed-article:20878981 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20878981 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20878981 | pubmed:volume | 129 | lld:pubmed |
| pubmed-article:20878981 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20878981 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20878981 | pubmed:pagination | 424-32 | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:meshHeading | pubmed-meshheading:20878981... | lld:pubmed |
| pubmed-article:20878981 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20878981 | pubmed:articleTitle | Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. | lld:pubmed |
| pubmed-article:20878981 | pubmed:affiliation | Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA. | lld:pubmed |
| pubmed-article:20878981 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20878981 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:20878981 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
